Design Therapeutics Inc (NAS:DSGN)
$ 6.35 0.14 (2.25%) Market Cap: 359.54 Mil Enterprise Value: 107.99 Mil PE Ratio: 0 PB Ratio: 1.42 GF Score: 40/100

Design Therapeutics Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript

Feb 15, 2023 / 10:00PM GMT
Release Date Price: $6.87 (+2.23%)
Joseph Schwartz
SVB Securities - Moderator

Hello. Welcome to this fireside chat with Design Therapeutics. I'm pleased to be joined by Joao Siffert, Chief Executive Officer. Thanks for joining us today.

Joao Siffert
Design Therapeutics, Inc. - CEO

Thank you. Yeah, thanks for having us.

Joseph Schwartz
SVB Securities - Moderator

So it's an exciting time for the company. Wondering if you can start us off with a brief overview of your GeneTAC platform technology, the key pipeline programs you're pursuing, and what catalysts they'll have over the next -- the rest of the year.

Joao Siffert
Design Therapeutics, Inc. - CEO

Okay. Thanks, Joe. So we're a pioneering in a very exciting new platform of small molecules that we call Gene Targeted Chimeras or GeneTAC molecules for short. And these are molecules that are capable of targeting a specific gene and harness the person's own cell mechanisms to either dial up or to dial down gene expression without any need for irreversible

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot